Tom Murphy | Associated Press

Rite Aid has been banned from using facial recognition technology for five years over allegations that its surveillance system was used incorrectly to identify potential shoplifters, especially Black, Latino, Asian or female shoppers.

Some private insurers are balking at paying for Leqembi, the first drug fully approved to slow mental decline in Alzheimer’s patients, because they still see it as experimental.